Characterization of Biological Nanoparticle Subsets

液体活组织检查是这一新兴生物医学研究前沿的一部分。生物学和医学的所有领域都对这一前沿领域感兴趣，尤其是癌症研究界。循环肿瘤细胞（CTC）和无细胞核酸（cfNAs）是两种类型的液体活检，在过去十年中，在了解这些CTC和cfNA肿瘤相关和基于系统的生物学信息方面取得了明显进展。由于缺乏稳健可靠的工具来正确测量亚微米和纳米级材料，对亚微米细胞外囊泡（ev）和其他纳米级大分子组件（以下统称为细胞外囊泡和颗粒，或evp）进行系统、准确和可重复的研究是困难的。CCR的使命是通过解决癌症研究和患者护理中重要的、具有挑战性的和被忽视的问题来改善所有癌症患者的生活。转化纳米生物学部分在CCR内的特殊专业知识，观点，合作和愿景正在建立桥梁，以跨越基础生物物理和计量学第一原理，先进的分子多组学策略和临床转化研究之间的现有差距，以便开发系统，强大和准确的方法来研究evp -肿瘤，免疫-，和基质/血管EVP组成，因为它们与癌症患者的肿瘤进展和治疗反应有关。虽然我的实验室的具体重点与癌症和癌症相关的免疫生物学最直接相关，但我们希望我们的工作能够成为生物医学研究界的一般资产。因此，我的部门致力于分享我们的工具用于一般研究，以便他们也可以加速其他疾病的研究。我的项目的最终目标是利用evp中的信息内容以系统的方式询问生物系统，也就是说，通过识别和表征evp的特定子集来“读取”这些子集所代表的隔室的状态。转化纳米生物学实验室项目1和项目2的目的是为该领域开发和演示新工具的使用，这些工具将使我们能够监测肿瘤、免疫和血管/基质系统，我们希望这种方式将使我们能够进行血液测试，以在放射或其他治疗过程的早期发现这些系统的相关变化。我们希望这将更广泛地作为未来选择性（特定系统）适应性治疗策略的基础。项目1的重点是填补现有工具和知识的空白，以准确表征项目2的液体活检成分，evp及其货物。

Liquid biopsies are part of this emerging frontier in biomedical research. This frontier is of interest to all areas of biology and medicine and is of particular interest to the cancer research community. Circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs) are two types of liquid biopsies where clear progress has been made in the past decade towards understanding these CTC and cfNA tumor-related and systems-based biological information. Systematic, accurate, and reproducible studies of sub-micron extracellular vesicles (EVs) and other nanoscale macromolecular assemblies (collectively referred to hereafter as extracellular vesicles and particles, or EVPs) are difficult to perform due to a lack of robust and reliable tools for correctly measuring these submicron and nanoscale materials. CCR's mission is to improve the lives of all cancer patients by solving important, challenging, and neglected problems in cancer research and patient care. The Translational Nanobiology Section's particular expertise, perspective, collaborations, and vision within CCR is building bridges to span the existing gaps between basic biophysical and metrological first principles, advanced molecular multi-omics strategies, and clinical translational investigation in order to develop systematic, robust, and accurate ways to study EVPs tumor-, immune-, and stromal-/vascular- EVP compositions as they relate to tumor progression and treatment response in our cancer patients. Although the specific focus of my lab pertains most immediately to cancer and cancer-related immunobiology, we intend for our work to be a general asset to the biomedical research community. As such, my Section is committed to sharing our tools for general research use, so that they can accelerate studies in other diseases as well. The ultimate goal of my program is to leverage the information content in EVPs to interrogate biological systems in a systematic manner, that is, by identification and characterization of specific sub-sets of EVPs to 'read' the status of compartments represented by those sub-sets. The purpose of Projects 1 and 2 in the Translational Nanobiology Lab is to develop and demonstrate the use of new tools for the field to use that will enable us to monitor tumor, immune, and vascular/stromal systems in a manner that we hope will enable us to perform blood tests to detect relevant changes in those systems early in the course of radiation or other therapies, and we hope that this will more broadly serve as a foundation for enabling selectively (system-specific) adaptive treatment strategies in the future. Project 1 is focused on spanning the gap in available tools and knowledge to accurately characterize the liquid biopsy components, EVPs and their cargo, for Project 2.